Joseph Michael Fitzgerald - Feb 16, 2024 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Feb 16, 2024
Transactions value $
-$374,647
Form type
4
Date filed
2/20/2024, 09:03 PM
Previous filing
Feb 16, 2024
Next filing
Feb 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +3.96K +2.12% $0.00 191K Feb 16, 2024 Direct F1
transaction BSX Common Stock Tax liability -$119K -1.81K -0.95% $65.82 189K Feb 16, 2024 Direct
transaction BSX Common Stock Options Exercise $0 +4.17K +2.21% $0.00 193K Feb 17, 2024 Direct F1
transaction BSX Common Stock Tax liability -$135K -2.06K -1.07% $65.82 191K Feb 17, 2024 Direct
transaction BSX Common Stock Options Exercise $0 +3.71K +1.94% $0.00 195K Feb 18, 2024 Direct F2
transaction BSX Common Stock Tax liability -$120K -1.83K -0.94% $65.82 193K Feb 18, 2024 Direct
holding BSX Common Stock 68K Feb 16, 2024 By 401(k) F3
holding BSX Common Stock 4.89K Feb 16, 2024 By Child F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Restricted Stock Units Options Exercise $0 -3.96K -33.33% $0.00 7.92K Feb 16, 2024 Common Stock 3.96K Direct F1, F5
transaction BSX Restricted Stock Units Options Exercise $0 -4.17K -50% $0.00 4.17K Feb 17, 2024 Common Stock 4.17K Direct F1, F6
transaction BSX Deferred Stock Units Options Exercise $0 -3.71K -100% $0.00* 0 Feb 18, 2024 Common Stock 3.71K Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.
F3 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F4 The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F5 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
F6 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.
F7 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.